Sanofi to acquire next-generation vaccine biotech Vicebio for US$1.6 billion
Sanofi will gain access to Molecular Clamp technology that enables development of next-generation multivalent vaccines against respiratory pathogens and beyond Lead asset VXB-241 is a bivalent vaccine targeting Respiratory Syncytial Virus (RSV) and Human Metapneumovirus (hMPV), currently in exploratory Phase 1 Upfront payment of US$1.15 billion and milestones up to US$450 million London, UK, 22 […]
Pharvaris Updates Timing of Topline Data Announcement for RAPIDe-3 Pivotal Phase 3 Study to the Fourth Quarter of 2025
Company expects to submit deucrictibant IR capsule NDA to the U.S. FDA for the on-demand treatment of HAE attacks in 1H2026
Candid Therapeutics Advances Portfolio of Novel T-Cell Engagers into Five Autoimmune Diseases for Clinical Evaluation
— First Patients Dosed with BCMA T-cell engager (cizutamig) and CD20 T-cell engager (CND261) — Clinical Studies in IgA Nephropathy, Myasthenia Gravis, Rheumatoid Arthritis, Systemic Lupus Erythemotosus and Systemic Sclerosis are Underway — CMC Established to Facilitate Global Clinical Trials — China Operations Established for Early Clinical Development San Diego, CA, June 20, 2025: Candid […]
Harmony Biosciences Strengthens Patent Position With Favorable Settlement in ANDA Litigation
PLYMOUTH MEETING, Pa.–(BUSINESS WIRE)–Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), today announced a settlement agreement with Lupin Limited, resolving the patent infringement litigation related to Lupin’s Abbreviated New Drug Application (ANDA) for a generic version of WAKIX® (pitolisant hydrochloride). As part of the agreement, litigation in the United States District Court for the District of Delaware […]
Pharvaris Presents Data Supporting Ongoing Clinical Development of Deucrictibant in Bradykinin-Mediated Angioedema
Deucrictibant data shows single-dose durability without symptom reoccurrence in the majority of HAE attacks treated First-ever bradykinin B2 receptor mechanism-on-mechanism prophylactic/on-demand data supports potential for deucrictibant portfolio Clinically validated biomarker assay has potential to eventually expand treatment opportunities of deucrictibant into additional forms of bradykinin-mediated angioedema Epidemiologic data and cognitive interviews further elucidate the unmet […]
Marea Therapeutics Announces Publication in The Lancet of Positive Data from Phase 2a Clinical Trial of MAR001 for Cardiovascular Disease
Publication follows late-breaking oral presentation of Phase 2a results at the 93rd EAS Congress; MAR001 demonstrated approximately 53% placebo-adjusted mean reductions in remnant cholesterol and triglycerides at 12 weeks
Second publication of MAR001 preclinical results in eBioMedicine that demonstrate improved plasma lipid profiles
Akero Therapeutics Announces Publication of Phase 2b SYMMETRY Trial in the New England Journal of Medicine
Results support potential benefit of efruxifermin (EFX) to elicit fibrosis improvement in patients with compensated cirrhosis (F4 fibrosis) due to MASH 96-week data from SYMMETRY trial presented at EASL Congress 2025 SOUTH SAN FRANCISCO, Calif., May 09, 2025 (GLOBE NEWSWIRE) — Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious […]
Harmony Biosciences Reports Strong Q1 2025 Financial Results, Highlights Advancement of Its Pipeline and Upcoming Catalysts, and Reaffirms 2025 Revenue Guidance
WAKIX® (pitolisant) Net Revenue of $184.7 Million for First Quarter 2025; Representing 20% Growth Year-over-Year; Reiterates Guidance of $820-$860M Net Income Grew 19% Year-over-Year, Building on Four Consecutive Years of Profitability; Increased Cash and Investments to Over $600 Million on Balance Sheet Completed Recruitment of Phase 3 Registrational Trial of ZYN002 in Fragile X Syndrome; […]
Abdera Therapeutics to Present Key Updates on its Radiopharmaceutical Development Pipeline at the 2025 American Association for Cancer Research (AACR) Annual Meeting
Dosing underway in Phase 1 clinical trial for ABD-147 (DLL3-targeting radiopharmaceutical) in patients with extensive stage small cell lung cancer and large cell neuroendocrine carcinoma of the lung; Abdera to present trial-in-progress posterPoster presentation of preclinical data for Abdera’s second development program, ABD-320, representing the first radiopharmaceutical therapy in development targeting 5T4
Attovia Therapeutics Announces $90 Million Series C Financing to Advance ATTOBODY-based Programs through Clinical Proof of Concept
Series C round led by Deep Track Capital with participation from additional new and existing investors Financing will fund early-to-mid-stage clinical studies for ATTO-1310 in chronic pruritus and ATTO-3712 in atopic dermatitis, and multiple earlier-stage multi-specific programs SAN CARLOS, Calif., April 15, 2025 (GLOBE NEWSWIRE) — Attovia Therapeutics, a privately-held, clinical-stage biopharma company developing treatments […]
